Kairos Pharma (KAPA) Other Non-Current Liabilities (2023)

Kairos Pharma's (KAPA) quarterly Other Non-Current Liabilities came in at $4000.0 in Q4 2023.

Kairos Pharma (KAPA) Other Non-Current Liabilities (2023) Analysis & Trends

Kairos Pharma (KAPA) has 1 years of Other Non-Current Liabilities data on file, last reported at $4000.0 in Q4 2023.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $4000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4000.0 (changed N/A YoY) and the FY2023 annual result came in at $4000.0, changed N/A from the prior year.
Other Non-Current Liabilities was little changed at $4000.0 in Q4 2023.
In the past five years, Other Non-Current Liabilities ranged from a high of $4000.0 in Q4 2023 to a low of $4000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Kairos Pharma	5.39 Mn	55,970.58	-

Download Data

Date	Value
Dec 31, 2023	4,000.00